Form 4: Dogwood Therapeutics Director John C. Thomas Reports Acquisition of Stock Options

Dogwood Therapeutics, Inc. Director John C. Thomas reported the acquisition of 2,362 stock options with an exercise price of $4.71, exercisable from June 27, 2026, and expiring on June 27, 2035.

Summary

• John C. Thomas, a Director of Dogwood Therapeutics, Inc. (DWTX), reported a transaction involving derivative securities.
• On June 27, 2025, Mr. Thomas acquired 2,362 stock options.
• Each option grants the right to buy one share of Dogwood Therapeutics Common Stock at an exercise price of $4.71.
• These options become exercisable on June 27, 2026, and have an expiration date of June 27, 2035.
• Following this transaction, Mr. Thomas directly beneficially owns 2,362 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is generally positive for governance and alignment of interests, but it is a small transaction and does not provide significant new information about the company's financial or operational performance.

Positives

• The grant of stock options to a director aligns their financial interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $4.71 indicates a specific valuation at the time of grant.

Negatives

• No negative information is presented in this Form 4 filing.

Risks

• This Form 4 does not disclose specific company risks; it is solely a transaction report.

Future Outlook

This Form 4 filing is a historical transaction report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

The grant of stock options to directors is a common practice across various industries, particularly in publicly traded companies, as a form of non-cash compensation designed to align the interests of the board with shareholders.

Comparison to Industry Standards

• The grant of 2,362 stock options to a director is a standard practice for equity compensation, comparable to similar grants observed in small to mid-cap biotechnology or pharmaceutical companies like Dogwood Therapeutics.
• The exercise price of $4.71 would typically be set at or above the fair market value of the common stock on the grant date, which is a common industry standard for incentive stock options.
• The 10-year expiration period (from 2025 to 2035) and a one-year vesting period (exercisable from 2026) are also typical structures for director stock option grants in the industry, aiming to encourage long-term commitment.

Related Party Transactions

• The acquisition of stock options by John C. Thomas, a Director of Dogwood Therapeutics, Inc., constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The grant of stock options to a director helps align the director's financial incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: This specific filing does not directly impact general employees, but it reflects the company's compensation practices for its leadership.

Next Steps

• The director may choose to exercise these options at any point between June 27, 2026, and June 27, 2035, assuming the stock price is above the exercise price of $4.71.
• Any future transactions involving these options (e.g., exercise and sale of underlying shares) would be reported in subsequent Form 4 filings.

Key Dates

Keywords

Dogwood Therapeutics, DWTX, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership